Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology and pharmaceutical company focused on therapies for pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, and other serious conditions, as well as technologies to expand the availability of transplantable organs. This news page aggregates company announcements, clinical updates, financial disclosures, and conference presentations related to UTHR.
Recent news highlights include detailed results from the TETON-2 phase 3 study of nebulized Tyvaso (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis, where United Therapeutics reported that the trial met its primary efficacy endpoint and achieved statistically significant improvements in several secondary endpoints. The company has also announced the first clinical xenotransplantation of its investigational UKidney xenokidney in the EXPAND study for patients with end-stage renal disease, reflecting its stated public benefit purpose of expanding access to transplantable organs.
Investors and followers of UTHR can review press releases on quarterly financial results, including product-level revenue disclosures for Tyvaso DPI, nebulized Tyvaso, Remodulin, Orenitram, Unituxin, Adcirca, and other items. Additional updates cover accelerated share repurchase agreements, stock incentive plan changes, and participation in major investor conferences hosted by firms such as J.P. Morgan, UBS, Jefferies, and Bernstein.
For those tracking developments in pulmonary hypertension, interstitial lung disease, xenotransplantation, and the company’s public benefit corporation activities, this news feed offers a centralized view of United Therapeutics’ clinical data presentations, regulatory milestones, and corporate actions. Bookmark this page to quickly access new UTHR press releases and related market-moving information as they are published.
United Therapeutics Corporation (Nasdaq: UTHR) reported a record revenue of $1.94 billion for the year ending December 31, 2022, marking an 18% increase from 2021. The fourth quarter revenues reached $491.5 million, an 18% rise year-over-year. Key products, especially Tyvaso, saw significant growth, with sales increasing 46% in Q4 and 44% for the full year. The company aims to double its revenue to a $4 billion run rate by 2025, driven by ongoing patient growth and pivotal clinical data expected for Tyvaso and ralinepag.
United Therapeutics Corporation (Nasdaq: UTHR) will announce its fourth quarter and full year 2022 financial results on February 22, 2023, before market opening. A public webcast will follow at 9:00 a.m. Eastern Time on the same day, accessible on the company's website. As a pioneering public benefit corporation, United Therapeutics focuses on developing novel pharmaceutical therapies and technologies to enhance organ transplant availability for patients. The company emphasizes its mission to address unmet medical needs through innovation and stakeholder benefit.
United Therapeutics Corporation (UTHR) has announced that Dr. Martine Rothblatt, CEO, will provide a business overview during a fireside chat at the 41st J.P. Morgan Healthcare Conference in San Francisco. The event is scheduled for Monday, January 9, 2023, from 1:30 p.m. to 2:10 p.m. PST. It will be accessible via live webcast on the United Therapeutics website, with an archived version available 24 hours post-event. United Therapeutics strives to innovate for unmet medical needs as a public benefit corporation.
Summary not available.
United Therapeutics Corporation (Nasdaq: UTHR) reported record financial results for Q3 2022, achieving revenues of $516.0 million, a 16% year-over-year increase. The net income soared to $239.3 million, a 47% increase from the prior year. Tyvaso emerged as a key revenue driver with sales of $257.7 million, a significant 57% increase year-over-year. The company is advancing clinical studies, including the recently launched TETON 2 study for idiopathic pulmonary fibrosis. The financial results underscore strong growth and successful commercialization strategies.
United Therapeutics Corporation (UTHR) announced that Patrick Poisson, Executive Vice President of Technical Operations, will present at the Credit Suisse 31st Annual Healthcare Conference in
United Therapeutics Corporation (Nasdaq: UTHR) announced preliminary results from the EXPEDITE study, which evaluates the efficacy of Remodulin induction in patients with pulmonary arterial hypertension (PAH). In this phase 4 study, 79% of participants achieved a total daily dose of 12 mg of Orenitram after an induction period. The study involved 36 patients, with 29 completing the trial, indicating a significant improvement in dosing efficiency over traditional methods. These findings suggest a potential shift in treatment protocols for PAH.
United Therapeutics Corporation (Nasdaq: UTHR) is set to release its third quarter 2022 financial results on November 2, 2022, before market opening. A public webcast will follow at 9:00 a.m. Eastern Time on the same day, accessible through the company's website. United Therapeutics, a public benefit corporation, focuses on developing innovative pharmaceutical therapies and expanding organ transplant availability. The announcement includes caution about forward-looking statements regarding future operations and potential risks involved.
United Therapeutics Corporation (NASDAQ: UTHR) announced data from the INCREASE and FREEDOM-EV open-label extension studies, showcasing long-term safety for Tyvaso and improved survival in pulmonary arterial hypertension (PAH) patients using Orenitram. Presentations will occur at the CHEST 2022 Annual Meeting, highlighting gaps in initial combination therapy strategies for PAH. Events include the CHEST Women & Pulmonary Luncheon and a symposium on PH-ILD. These findings aim to enhance treatment strategies and outcomes for patients suffering from pulmonary hypertension.
United Therapeutics Corporation (Nasdaq: UTHR) has announced the enrollment of the first patient in the phase 3 TETON 2 study, involving 396 adult patients with idiopathic pulmonary fibrosis (IPF). This 52-week registration study aims to assess the impact of Tyvaso on forced vital capacity (FVC), a key prognostic indicator for IPF. The TETON program further investigates the antifibrotic effects of inhaled treprostinil. IPF is characterized by progressive lung scarring, leading to severe respiratory complications.